Moreover, the observation of baseline NRAS and MAP2K1 mutations concomitantly with BRAF mutation in 17 (26.6%) patients are consistent with the 24% rate reported by Johnson et al. [20] in relapsed tumor samples and confirm the implication of these mutations in BRAF inhibitor resistance. The gene discussed is MAP2K1; the disease is neoplasm.